10-Q: GT Biopharma Q1 2026 Results: Net Loss Widens Amidst SG&A Increase

GT Biopharma reports a wider net loss for Q1 2026 compared to the prior year, driven by increased selling, general, and administrative expenses, while research and development costs decreased.

Summary

• GT Biopharma reported a net loss of $2.83 million for the three months ended March 31, 2026, a significant increase from the $776,000 net loss in the same period of 2025.
• Operating expenses rose by 47% to $2.85 million, primarily due to a 188% increase in selling, general and administrative (SG&A) expenses, which climbed to $2.44 million from $833,000.
• Research and development (R&D) expenses decreased by 62% to $413,000, attributed to a reduction in production costs.
• Cash and cash equivalents increased to $9.02 million as of March 31, 2026, from $2.46 million at the end of the prior year period, bolstered by financing activities.
• The company continues to operate as a clinical-stage biopharmaceutical company with no approved products and expects ongoing losses, raising substantial doubt about its ability to continue as a going concern.
• The company received FDA clearance for its IND application for GTB-3650 in June 2024 and began patient enrollment in January 2025. For GTB-5550, the IND application was cleared in January 2026, with the first patient dosed in May 2026.
• The company is facing a potential delisting from the Nasdaq Capital Market due to its stock price closing below $1 for 30 consecutive business days and has requested an additional 180-day compliance period.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the widening net loss, significant increase in SG&A expenses, and the critical risk of Nasdaq delisting, despite positive developments in clinical trial progress.

Positives

• Cash and cash equivalents increased significantly to $9.02 million as of March 31, 2026, up from $2.46 million in the prior year period, indicating improved liquidity.
• Financing activities provided $4.58 million in net cash for the three months ended March 31, 2026, primarily from the issuance of Series L Preferred Stock and warrants.
• Research and development expenses decreased by 62% to $413,000, suggesting improved cost management in R&D activities.
• The company received FDA clearance for its IND application for GTB-3650 in June 2024 and for GTB-5550 in January 2026, allowing for continued clinical development.
• Patient enrollment for the GTB-3650 clinical trial began in early 2025, with approximately 50% of patients dosed.
• The first patient for the GTB-5550 clinical trial was dosed in May 2026.

Negatives

• Net loss for the three months ended March 31, 2026, was $2.83 million, a substantial increase from $776,000 in the same period of 2025.
• Selling, general, and administrative expenses increased by 188% to $2.44 million for the three months ended March 31, 2026, compared to $833,000 in the prior year period.
• The company's independent auditors have raised substantial doubt about its ability to continue as a going concern.
• The company is not in compliance with Nasdaq's minimum bid price requirement and faces potential delisting.
• The company has not generated any revenue from product sales and expects ongoing losses.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to sustained operating losses and the need for future financing.
• Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to delisting, adversely affecting the ability to raise capital, liquidity, and stock price volatility.
• The company has no product candidates approved for sale and has not generated revenue, with ongoing losses expected.
• The company is involved in several legal proceedings, including an arbitration demand against its former CFO and ongoing disputes related to convertible notes and securities purchase agreements.
• The company's stock price has fallen below $1, triggering a potential delisting from the Nasdaq Capital Market.

Future Outlook

The company expects ongoing operating losses into the foreseeable future. Its ability to continue as a going concern is subject to substantial doubt, contingent upon securing additional financing. The company is actively pursuing clinical development of its product candidates GTB-3650 and GTB-5550, with IND applications cleared by the FDA and patient enrollment underway or initiated.

Management Comments

• The company believes its TriKE and Dual Targeting TriKE platforms that activate endogenous NK cells are potentially safer than T-cell immunotherapy because there is less cytokine release syndrome (CRS) and fewer neurological complications.
• Preclinical data suggests that the TriKE dependent CD16 directed IL-15 proliferation of NK cells has little effect on endogenous T cells.
• The company believes its TriKEs may have the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies.
• The company is advancing GTB-3650 to clinical studies based on pre-clinical data showing a marked increase in potency compared to GTB-3550, which we anticipate could lead to an enhanced efficacy signal in AML and MDS.
• The company intends to monitor the closing bid price of the common stock and assess its available options to regain compliance with the Minimum Bid Price requirement and continue listing on The Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that GT Biopharma's focus on immuno-oncology, specifically its TriKE and Dual Targeting TriKE platforms, aligns with a significant trend in cancer therapy development. The company's strategy to leverage NK cells and camelid nanobody technology positions it within a competitive but rapidly evolving segment of the biopharmaceutical industry. The challenges faced with Nasdaq listing compliance are common for clinical-stage companies requiring substantial capital for development.

Comparison to Industry Standards

• The company's net loss of $2.83 million for the quarter is substantial for a clinical-stage biopharmaceutical company, but the magnitude of losses can vary widely depending on the stage of development and R&D spending.
• The increase in SG&A expenses by 188% is a significant deviation from typical operational efficiency metrics and warrants scrutiny, potentially indicating increased marketing, legal, or administrative costs.
• The decrease in R&D expenses by 62% could be viewed positively if it reflects efficient resource allocation or a shift in focus to more promising candidates, but it could also signal a slowdown in pipeline advancement.
• The company's cash burn rate of approximately $2.5 million for the quarter, while significant, is within the range expected for companies in this sector, but its sustainability is heavily reliant on future financing.
• The Nasdaq delisting risk is a critical concern, as maintaining a listing on a major exchange is a standard benchmark for companies seeking to attract institutional investors and facilitate liquidity.

Corporate Governance

Legal Proceedings

• AAA Arbitration Demand filed by the Company against former CFO Manu Ohri for breach of fiduciary duties and contract. Mr. Ohri filed counterclaims. Final hearing scheduled for October 6-8, 2026.
• Z-One, LLC filed a notice of appeal on March 26, 2026, regarding the dismissal of its claims for breach of a convertible note. The appeal must be perfected by September 25, 2026.
• The Company reached a settlement in principle with Coby Silberfein, Justin DiPietro, and Phillip Werthman Trust regarding claims for breach of convertible notes and securities purchase agreements, with settlement terms being finalized.

Related Party Transactions

• The Company entered into an Advisory Agreement with PDPC Advisors Inc., whose CEO has voting and investment control over an entity exceeding 5% beneficial ownership of the Company's common stock. Cash payments and a pre-funded warrant were issued.

Stakeholder Impact

• Shareholders: Potential delisting from Nasdaq could negatively impact stock liquidity, price volatility, and the ability to obtain accurate quotations. Dilution risk exists from potential future capital raises.
• Creditors: The company's going concern status and ongoing losses may impact its ability to meet financial obligations.
• Employees: Continued uncertainty regarding the company's financial stability and Nasdaq listing could affect morale and future employment prospects.
• Suppliers: Increased SG&A expenses may include higher legal fees, potentially impacting the company's ability to meet payment obligations to vendors.

Next Steps

• Continue clinical development of GTB-3650 and GTB-5550.
• Seek additional financing to fund operations and address going concern issues.
• Regain compliance with Nasdaq's minimum bid price requirement to avoid delisting.
• Finalize settlement agreements for the Silberfein, DiPietro, and Werthman Trust matters.
• Continue to monitor and manage legal proceedings.

Key Dates

Recommendation

While GT Biopharma shows promising clinical development progress with FDA IND clearances for key drug candidates (GTB-3650 and GTB-5550), the significant increase in net loss, substantial rise in SG&A expenses, and the critical risk of Nasdaq delisting due to the low stock price present considerable headwinds. The company's going concern status remains a major concern, heavily reliant on future financing. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor the company's ability to secure funding, regain Nasdaq compliance, and manage its operational expenses while awaiting further clinical data.

Keywords

GT Biopharma, 10-Q, Quarterly Report, Biopharmaceutical, Immuno-oncology, TriKE, GTB-3650, GTB-5550, Clinical Stage, FDA, Nasdaq, Delisting, Net Loss, Going Concern